Followers | 504 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
![](https://investorshub.advfn.com/uicon/475374.png?cb=1683825270)
Monday, May 18, 2015 5:08:21 PM
bullish
triangle resistance breakout
macd crossup
in the top bollinger band area
## source: finance.yahoo.com
Mon, 18 May 2015 20:21:44 GMT ~ Healthcare Winners and Losers: May 18, 2015
read full: http://finance.yahoo.com/video/healthcare-winners-losers-may-6-202126519.html
*********************************************************
Mon, 18 May 2015 16:51:27 GMT ~ Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference
[at noodls] - - Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway - Paris and Tarrytown, NY - May 18, 2015-Sanofi and Regeneron Pharmaceuticals, Inc. today shared additional positive results from an ...
read full: http://www.noodls.com/view/815ABAFFD2360AAE5EB82D15F0A60C9682DE544F
*********************************************************
Mon, 18 May 2015 16:31:00 GMT ~ 12:31 pm Regeneron Pharms and Sanofi (SNY) announce positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#regn
*********************************************************
Mon, 18 May 2015 16:30:00 GMT ~ Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference
[PR Newswire] - TARRYTOWN, N.Y. and PARIS, May 18, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA). As previously reported, the study met its primary endpoint of improving lung function in asthma patients with high blood eosinophil counts (HEos, greater than or equal to 300 eosinophilic cells/microliter). Such high counts are thought to be a marker for patients more likely to have "atopic" or "allergic" asthma. New data presented on secondary endpoints at the American Thoracic Society 2015 International Conference included positive results in study patients with low blood eosinophil counts (LEos, less than 300 eosinophilic cells/microliter), who are thought to be less likely to suffer from "allergic" asthma and thus less likely to respond to TH2 targeted therapies.
read full: http://finance.yahoo.com/news/regeneron-sanofi-announce-positive-pivotal-163000724.html
*********************************************************
Mon, 18 May 2015 15:33:00 GMT ~ Regeneron: Why It's Heading to $550
read full: http://blogs.barrons.com/stockstowatchtoday/2015/05/18/regeneron-why-its-heading-to-550/?mod=yahoobarrons&ru=yahoo
*********************************************************
$REGN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$REGN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/REGN/company-info
Ticker: $REGN
OTC Market Place: Not Available
CIK code: 0000872589
Company name: Regeneron Pharmaceuticals, Inc.
Incorporated In: NY, USA
$REGN share structure
## source: otcmarkets.com
Market Value: $49,539,462,703 a/o May 15, 2015
Shares Outstanding: 101,305,623 a/o Apr 16, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$REGN extra dd links
Company name: Regeneron Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/REGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/REGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=REGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=REGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=REGN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/news - http://finance.yahoo.com/q/h?s=REGN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/REGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/REGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/REGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/REGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=REGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/REGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Regeneron+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Regeneron+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Regeneron+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/REGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/REGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/REGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/REGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/REGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/REGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=REGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=REGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=REGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=REGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=REGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=REGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=REGN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/REGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=REGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/REGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=REGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/REGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/REGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/REGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/REGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/REGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=REGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=REGN
$REGN DD Notes ~ http://www.ddnotesmaker.com/REGN
Recent REGN News
- EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile • GlobeNewswire Inc. • 09/11/2024 11:00:46 AM
- Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer • GlobeNewswire Inc. • 09/09/2024 09:00:00 PM
- Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO • GlobeNewswire Inc. • 09/09/2024 11:00:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:01:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:01:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:01:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:04:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:27:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:35:33 PM
- Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma • GlobeNewswire Inc. • 08/26/2024 11:00:00 AM
- Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases • GlobeNewswire Inc. • 08/26/2024 05:00:00 AM
- Regeneron Provides Update on Biologics License Application for Linvoseltamab • GlobeNewswire Inc. • 08/20/2024 10:45:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:02:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:01:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 09:55:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:01:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 03:45:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:08:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:01:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 08:05:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2024 08:53:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:40:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:33:34 PM
- Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast • GlobeNewswire Inc. • 08/07/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:03:46 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM